• Aclaris Therapeutics priced an underwritten offering expected to raise approximately $50 million in gross proceeds before fees and expenses.
• The offering comprises 7,785,714 common shares at $3.50 per share.
• Pre-funded warrants to purchase 6,500,000 common shares were priced at $3.49999 per share in lieu of shares for certain investors.
• Closing is expected on October 28, 2026, subject to customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270643PRIMZONEFULLFEED9853890) on October 27, 2026, and is solely responsible for the information contained therein.